Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01769690 · ClinicalTrials.gov registry record · NA

The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients

A NA study of Parkinson's Disease, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT01769690 is a NA study of Parkinson's Disease that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01769690, a NA study of Parkinson's Disease, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The study design is a within-subject randomized cross-over design to evaluate the effects of DBS on sleep architecture, as measured by polysomnography, and on wake-time vigilance, as measured by a virtual reality street-crossing simulator.

Conditions Studied

Interventions

  • OTHER DBS stimulator setting alteration
  • OTHER virtual reality simulator

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-12
Est. Completion 2020-02
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT01769690

The ClinicalTrials.gov registry entry for NCT01769690 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (97% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which DBS stimulator setting alteration is the first listed.

NCT01769690 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT01769690 about?

NCT01769690 is a clinical study titled "The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients". The study design is a within-subject randomized cross-over design to evaluate the effects of DBS on sleep architecture, as measured by polysomnography, and on wake-time vigilance, as measured by a virtual reality street-crossing simulator.

What is the current status of trial NCT01769690?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2012-12. Estimated completion is 2020-02.

What conditions does trial NCT01769690 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT01769690?

The interventions under investigation include: DBS stimulator setting alteration (OTHER), virtual reality simulator (OTHER).

Who is sponsoring clinical trial NCT01769690?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01769690 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.